Citalopram Hydrobromide

CHEMBL1200781 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
405.3 g/mol
LogP
Phase
4

The hydrobromide salt is the standard oral formulation of citalopram used clinically for depression and anxiety disorders. It shares the same SSRI mechanism and dose-dependent QT prolongation risk as the parent compound. Gradual dose titration is recommended to minimize side effects including nausea and activation symptoms.

น้ำหนักโมเลกุล

405.3000 g/mol

TPSA

36.30 Ų

ด้านการรักษา

กลไกการออกฤทธิ์

Selectively inhibits the serotonin reuptake transporter (SERT) at presynaptic neurons, increasing serotonin concentration in the synaptic cleft. This enhanced serotonergic neurotransmission is associated with antidepressant and anxiolytic effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Selectively inhibits the serotonin reuptake transporter (SERT) at presynaptic neurons, increasing serotonin concentration in the synaptic cleft. This enhanced serotonergic neurotransmission is associated with antidepressant and anxiolytic effects.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Br.CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21

InChI

InChI=1S/C20H21FN2O.BrH/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20;/h4-9,12H,3,10-11,14H2,1-2H3;1H

Molecular Formula

C20H22BrFN2O

HBD / HBA

1 / 4

พันธะที่หมุนได้

5

อะตอมหนัก

25

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

The hydrobromide salt is the standard oral formulation of citalopram used clinically for depression and anxiety disorders. It shares the same SSRI mechanism and dose-dependent QT prolongation risk as the parent compound. Gradual dose titration is recommended to minimize side effects including nausea and activation symptoms.

Selectively inhibits the serotonin reuptake transporter (SERT) at presynaptic neurons, increasing serotonin concentration in the synaptic cleft. This enhanced serotonergic neurotransmission is associated with antidepressant and anxiolytic effects.

Yes, Citalopram Hydrobromide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200781. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 77995. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.